STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Brain Sciences Review Article

Study on Chemical Insights into Alzheimer's Disease: Amyloid Beta and Tau Protein Interactions

  1. Dhamodharan P

Abstract

Background: Alzheimers disease (AD) is the most prevalent form of dementia, affecting millions of individuals worldwide and posing significant challenges to healthcare systems. The disease is characterized by a gradual decline in cognitive functions, particularly memory, reasoning, and the ability to perform daily activities. Aim & objective: To study chemical insights in alzheimers disease, especially amyloid beta and tau protein interactions Results & discussion: The results of this review highlight several key findings regarding the molecular mechanisms involved in Alzheimers disease (AD) and their implications for understanding the diseases progression and potential therapeutic targets. It discussed these Amyloid-Beta and Tau Protein Interactions, Role of Advanced Glycation End Products (AGEs), Neuroinflammation and Oxidative Stress, Genetic and Environmental Risk Factors, and Therapeutic Implications.

Conclusion: The Biochemical mechanisms underlying Alzheimers disease (AD), focusing on the interactions between amyloid-beta (Aβ) and tau proteins, which are central to the diseases pathogenesis. It highlights the complex interplay of genetic and environmental risk factors contributing to AD and also emphasizes the need for ongoing research to develop effective therapeutic strategies targeting these molecular pathways.

Keywords

References (147)

  1. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement.
  2. 2018;14:367–429.
  3. Ulery PG, Strickland DK. LRP in Alzheimer’s disease: Friend or foe? J Clin Investig.
  4. 2000;106:1077–9.
  5. Sabbagh MN. FDA Position Statement Early Alzheimer’s Disease: Developing Drugs for
  6. Treatment, Guidance for Industry. Amsterdam: Elsevier; 2019. p. 13–19.
  7. Menendez-Gonzalez M, Padilla-Zambrano HS, Alvarez G, Capetillo-Zarate E, Tomas-Zapico C,
  8. Costa A. Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s
  9. Disease. Front Aging Neurosci. 2018;10:100.
  10. Lee LL. Discovery of amyloid-beta aggregation inhibitors using an engineered assay for
  11. intracellular protein folding and solubility. Protein Sci. 2009;18:277–86.
  12. Deane R, Sagare A, Zlokovic BV. The role of the Cell Surface LRP and Soluble LRP in Blood-
  13. Brain Barrier Aβ Clearance in Alzheimer’s Disease. Curr Pharm Des. 2008;14:1601–5.
  14. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al. Involvement of
  15. microglial receptor for advanced glycation end products (RAGE) in Alzheimer’s disease:
  16. Identification of a cellular activation mechanism. Exp Neurol. 2001;171:29–45.
  17. Deane RJ. Is RAGE still a therapeutic target for Alzheimer’s disease? Future Med Chem.
  18. 2012;4:915–25.
  19. Dhananjayan K, Forbes J, Munch G. Advanced Glycation, Diabetes, and Dementia. In: Type 2
  20. Diabetes and Dementia. Cambridge: Academic Press; 2018. p. 169–93.
  21. Saleh A, Smith DR, Tessler L, Mateo AR, Martens C, Schartner E, et al. Receptor for advanced
  22. glycation end-products (RAGE) activates divergent signalling pathways to augment neurite
  23. outgrowth of adult sensory neurons. Exp Neurol. 2013;249:149–59.
  24. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates
  25. amyloid-beta peptide transport across the blood-brain barrier and accumulation in the
  26. brain. Structure. 2011;19:722–32.
  27. Koch M. Structural basis for ligand recognition and activation of RAGE. Structure.
  28. 2010;18:1342–52.
  29. Haupt C, Bereza M, Kumar ST, Kieninger B, Morgado I, Hortschansky P, et al. Pattern
  30. recognition with a fibril-specific antibody fragment reveals the surface variability of natural
  31. amyloid fibril. J Mol Biol. 2011;408:529–40.
  32. Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, et al. Advanced glycation end product
  33. recognition by the receptor for AGEs. Structure. 2011;19:722–32.
  34. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, et al. Advanced glycation
  35. endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging.
  36. 2011;32:763–77.
  37. Loske C, Gerdemann A, Schell W, Wycislo M, Schinzel R, Palm D, et al. Transition metal-
  38. mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem.
  39. 2000;267:4171–8.
  40. World Health Organization. The Top 10 Causes of Death. 2018. Available from:
  41. https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death
  42. World Health Organization and Alzheimer’s Disease International. Dementia: a Public Health
  43. Priority. Geneva: World Health Organization; 2012. ISBN 978-92-4-156445-8.
  44. Alzheimer’s Disease International. World Alzheimer Report 2018. London; 2018. Available
  45. from: https://www.alz.co.uk/research/world-report-2018
  46. McGurran H, Glenn JM, Madero EN, Bott NT. Prevention and treatment of Alzheimer's
  47. disease: biological mechanisms of exercise. J Alzheimers Dis. 2019;69:311–38.
  48. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, et al. The P2Y12 receptor
  49. regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006;9:1512–9.
  50. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic
  51. reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.
  52. Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, et al. Dual microglia
  53. effects on blood-brain barrier permeability induced by systemic inflammation. Nat Commun.
  54. 2019;10:5816.
  55. Liu F, Cheng X, Zhong S, Liu C, Jolkkonen J, Zhang X, et al. Communications between
  56. peripheral and the brain-resident immune system in neuronal regeneration after stroke.
  57. Front Immunol. 2020;11:1931.
  58. Jurcau A, Simion A. Neuroinflammation in cerebral ischemia and ischemia/reperfusion
  59. injuries: From pathophysiology to therapeutic strategies. Int J Mol Sci. 2021;23:14.
  60. Ransohoff RM. A polarizing question: Do M1 and M2 microglia exist? Nat Neurosci.
  61. 2016;19:987–91.
  62. Spittau B. Aging microglia—Phenotypes, functions and implications for age-related
  63. neurodegenerative diseases. Front Aging Neurosci. 2017;9:194.
  64. Haas RH. Mitochondrial dysfunction in ageing and diseases of ageing. Biology. 2019;8:48.
  65. Picca A, Lezza AMS, Leeuwenburgh C, Pesce V, Calvani R, Landi F, et al. Fueling inflammation
  66. through mitochondrial dysfunction: Mechanisms and molecular targets. Int J Mol Sci.
  67. 2017;18:933.
  68. Barbosa MC, Grosso RA, Fader CM. Hallmarks of ageing: An autophagic perspective. Front
  69. Endocrinol. 2019;9:790.
  70. Hegde AN, Smith SG, Duke LM, Pourquoi A, Vaz S. Perturbations of ubiquitin-
  71. proteasome-mediated proteolysis in ageing and Alzheimer’s disease. Front Aging
  72. Neurosci. 2019;11:324.
  73. Chen G, Yung R. Meta-inflammaging at the crossroads of geroscience. Aging Med.
  74. 2019;2(3):157–61.
  75. Shintouo CM, Mets T, Beckwee D, Bautmans I, Ghogomu SM, Souopgui J, et al. Is
  76. inflammageing influenced by the microbiota in the aged gut? A systematic review.
  77. Exp Gerontol. 2020;141:111079.
  78. Onyango IG, Jauregui GV, Carnă M, Bennett JP Jr, Stokin GB. Neuroinflammation in
  79. Alzheimer’s disease. Biomedicines. 2021;9(5):524.
  80. Bradburn S, Sarginson J, Murgatroyd CA. Association of peripheral interleukin-6
  81. with global cognitive decline in nondemented adults: A meta-analysis of prospective
  82. studies. Front Aging Neurosci. 2018;9:438.
  83. Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP, et al.
  84. Association of inflammatory mediators with frailty status in older adults: Results from
  85. a systematic review and meta-analysis. GeroScience. 2020;42(6):1451–73.
  86. Picca A, Calvani R, Coelho-Júnior HJ, Marini F, Landi F, Marzetti E. Circulating
  87. inflammatory, mitochondrial dysfunction, and senescence-related markers in older
  88. adults with physical frailty and sarcopenia: A BIOSPHERE exploratory study. Int J
  89. Mol Sci. 2022;23(24):14006.
  90. Harré E-M, Roth J, Gerstberger R, Hübschle T. Interleukin-6 mediates
  91. lipopolysaccharide-induced nuclear STAT3 translocation in astrocytes of rat sensory
  92. circumventricular organs. Brain Res. 2003;980(2):151–5.
  93. Jurcau A. Insights into the pathogenesis of neurodegenerative diseases: Focus on
  94. mitochondrial dysfunction and oxidative stress. Int J Mol Sci. 2021;22(21):11847.
  95. Bolaños JP, Almeida A, Moncada S. Glycolysis: A bioenergetic or a survival
  96. pathway? Trends Biochem Sci. 2010;35(3):145–9.
  97. Brand MD. The sites and topology of mitochondrial superoxide production. Exp
  98. Gerontol. 2010;45(7–8):466–72.
  99. Stefanatos R, Sanz A. The role of mitochondrial ROS in the ageing brain. FEBS Lett.
  100. 2017;592(5):743–58.
  101. Jurcau A, Ardelean AI. Oxidative stress in ischemia/reperfusion injuries following
  102. acute ischemic stroke. Biomedicines. 2022;10(3):574.
  103. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species.
  104. Mol Cell. 2012;48(2):158–67.
  105. Milenkovic D, Blaza JN, Larsson NG, Hirst J. The enigma of the respiratory chain
  106. supercomplex. Cell Metab. 2017;25(4):765–76.
  107. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol
  108. Med. 2011;51(7):1289–301.
  109. Paß T, Wiesner RJ, Pla-Martin D. Selective neuron vulnerability in common and rare
  110. diseases–mitochondria in the focus. Front Mol Biosci. 2021;8:676187.
  111. Thomsen K, Yokota T, Hasan-Olive MM, Sherazi N, Fakouri NB, Desler C, et al.
  112. Initial brain ageing: Heterogeneity of mitochondrial size is associated with a decline
  113. in complex I-linked respiration in the cortex and hippocampus. Neurobiol Aging.
  114. 2018;61:215–24.
  115. Stahon KE, Bastian C, Griffith S, Kidd GJ, Brunet S, Baltan S. Age-related changes
  116. in axonal and mitochondrial ultrastructure and function in white ma tter. J
  117. Neurosci. 2016;36(37):9990–10001.
  118. Pollard AK, Craig EL, Chakrabarti L. Mitochondrial complex I activity measured by
  119. spectrophotometry is reduced across all brain regions in ageing and more specifically
  120. in neurodegeneration. PLoS One. 2016;11(6):e0157405.
  121. Hiona A, Sanz A, Kujoth GC, Pamplona R, Seo AY, Hofer T, et al. Mitochondrial
  122. DNA mutations induce mitochondrial dysfunction, apoptosis and sarcopenia in the
  123. skeletal muscle of mitochondrial DNA mutator mice. PLoS One. 2010;5(7):e11468.
  124. Zia A, Pourbagher-Shahri AM, Farkhondeh T, Samarghandian S. Molecular and
  125. cellular pathways contributing to brain ageing. Behav Brain Funct. 2021;17(1):6.
  126. Sharma C, Kim S, Nam Y, Jung UJ, Kim SR. Mitochondrial dysfunction as a driver of
  127. cognitive impairment in Alzheimer’s disease. Int J Mol Sci. 2021;22(9):4850.
  128. Kowald A, Kirkwood TBL. Resolving the enigma of the clonal expansion of mtDNA
  129. deletions. Genes. 2018;9(3):126.
  130. Jurcău MC, Andronie-Cioara FL, Jurcău A, Marcu F, Tit DM, Pascălău N, et al. The
  131. link between oxidative stress, mitochondrial dysfunction and neuroinflammation in
  132. the pathophysiology of Alzheimer’s disease: Therapeutic implications and future
  133. perspectives. Antioxidants. 2022;11(11):2167.
  134. Pinto M, Moraes CT. Mechanisms linking mtDNA damage and ageing. Free Radic
  135. Biol Med. 2015;85:250–8.
  136. Jurk D, Wang C, Miwa S, Maddick M, Korolchuk V, Tsolou A, et al. Postmitotic
  137. neurons develop a p21-dependent senescence-like phenotype driven by a DNA
  138. damage response. Aging Cell. 2012;11(6):996–1004.
  139. Tan S, Sagara Y, Liu Y, Maher P, Schubert D. The regulation of reactive oxygen
  140. species production during programmed cell death. J Cell Biol. 1998;141(6):1423–32.
  141. Holper L, Ben-Shachar D, Mann JJ. Multivariate meta-analyses of mitochondrial
  142. complex I and IV in major depressive disorder, bipolar disorder, schizophrenia,
  143. Alzheimer’s disease, and Parkinson’s disease. Neuropsychopharmacology.
  144. 2019;44(5):837–49.
  145. Beckervordersandforth R, Ebert B, Schäffner I, Moss J, Fiebig C, Shin J, et al. Role of
  146. mitochondrial metabolism in the control of early lineage progression and ageing
  147. phenotypes in adult hippocampal neurogenesis. Neuron. 2017;93(3):560–73.